Enliven Therapeutics (ELVN) Research & Development (2019 - 2026)

Enliven Therapeutics has disclosed Research & Development across 8 years of filings, most recently posting $20.7 million for Q1 2026.

• Research & Development for Q1 2026 came in at $20.7 million, down 16.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.6 million (down 4.73% YoY), and the FY2025 annual result was $85.9 million, up 6.29% from the prior year.
• Research & Development came in at $20.7 million for Q1 2026 at Enliven Therapeutics, down from $21.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $24.9 million in Q1 2025 to a low of $7.1 million in Q1 2022.
• The 5-year median for Research & Development is $18.8 million (2024), against an average of $16.6 million.
• Across the five-year window, Research & Development fell 24.7% in 2022 and surged 150.43% in 2023, its largest moves.
• Enliven Therapeutics' Research & Development stood at $8.2 million in 2022, then soared by 118.43% to $17.9 million in 2023, then gained by 15.74% to $20.7 million in 2024, then rose by 2.51% to $21.2 million in 2025, then fell by 2.63% to $20.7 million in 2026.
• The last three Research & Development figures came in at $20.7 million (Q1 2026), $21.2 million (Q4 2025), and $18.2 million (Q3 2025), per Business Quant data.